Aspirin + Ipilimumab + Pembrolizumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage III Cutaneous Melanoma
Conditions
Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Trial Timeline
Apr 19, 2018 → Jun 30, 2022
NCT ID
NCT03396952About Aspirin + Ipilimumab + Pembrolizumab
Aspirin + Ipilimumab + Pembrolizumab is a phase 2 stage product being developed by Merck for Stage III Cutaneous Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03396952. Target conditions include Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Stage III Cutaneous Melanoma were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03396952 | Phase 2 | Completed |
Competing Products
20 competing products in Stage III Cutaneous Melanoma